Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917710 | 0.94 | EPHX2 (0.76) | EPHX2EPHX1 | |
| SCHEMBL918144 | 0.94 | EPHX2 (0.76) | EPHX2EPHX1 | |
| SCHEMBL13330471 | 0.92 | EPHX1 (0.64) | EPHX2EPHX1MEN1KMT2A | |
| SCHEMBL23328387 | 0.92 | EPHX1 (0.67) | EPHX2EPHX1MEN1HTTKMT2A | |
| SCHEMBL14178998 | 0.89 | EPHX2 (0.58) | EPHX2EPHX1MEN1KMT2AALDH1A1 | |
| SCHEMBL30786047 | 0.85 | EPHX1 (0.90) | EPHX2EPHX1 | |
| SCHEMBL23329077 | 0.84 | EPHX2 (0.50) | EPHX2EPHX1MEN1HTTKMT2A | |
| SCHEMBL23328732 | 0.84 | EPHX1 (0.67) | EPHX2EPHX1MEN1HTTKMT2A | |
| SCHEMBL17991831 | 0.84 | EPHX2 (0.55) | EPHX2EPHX1MEN1HTTKMT2A | |
| SCHEMBL17133784 | 0.83 | EPHX1 (0.95) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | EPHX2 2581/4885EPHX1 2158/4885MEN1 1300/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | EPHX2 2581/4885EPHX1 2158/4885MEN1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.